http://www.cardiome.com/
According to analyst David Dean, those catalysts included European approval in mid-2010 of the IV version of Cardiome’s vernakalant drug to treat atrial fibrillation and a decision by partner Merck (NYSE:MRK) to start a Phase 3 clinical trial for the oral version of vernakalant, a potential blockbuster indication. ”Cardiome has what we believe is the most compelling active ingredient against atrial fibrillation, a market that is expected to increase meaningfully given the aging demographic.
Mr. Dean figures that the IV treatment could receive FDA approval in 2013 and the oral version by 2015. By the end of 2010, he expects the company will have financial resources of some $200 million, “sufficient to fund operations until Cardiome is cash flow positive.”
Aucun commentaire:
Enregistrer un commentaire